Peptide LibraryEptifibatide dosage in published studies and labels
These are the doses used for Eptifibatide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Eptifibatide has an FDA-approved human dosage as a hospital intravenous treatment for acute coronary syndrome and for patients undergoing percutaneous coronary intervention (PCI). The label gives a 180 mcg/kg intravenous bolus followed by a continuous infusion of 2 mcg/kg/min, with a second 180 mcg/kg bolus 10 minutes after the first for PCI, and reduces the infusion to 1 mcg/kg/min when creatinine clearance is below 50 mL/min.
| Human dosing established | Yes |
|---|---|
| Route | Intravenous |
| Frequency | Intravenous bolus followed by continuous infusion |
| Duration studied | Acute coronary syndrome: up to 72 hours. PCI: until hospital discharge or up to 18–24 hours, with at least 12 hours recommended |
| Half-life | About 2.5 hours (plasma elimination half-life) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — acute coronary syndrome (unstable angina or NSTEMI)FDA-approved label · FDA prescribing information | Adults with acute coronary syndrome managed medically or with PCI | 180 mcg/kg bolus as soon as possible after diagnosis, then 2 mcg/kg/min; 1 mcg/kg/min if creatinine clearance is below 50 mL/min | Intravenous | Bolus, then continuous infusion | Until hospital discharge or the start of bypass surgery, up to 72 hours | Indicated to decrease the rate of a combined endpoint of death or new myocardial infarction | Eptifibatide injection (Slate Run Pharmaceuticals) — FDA prescribing information, DailyMed |
| FDA label — percutaneous coronary intervention, including stentingFDA-approved label · FDA prescribing information | Adults undergoing PCI | 180 mcg/kg bolus immediately before PCI, then 2 mcg/kg/min, with a second 180 mcg/kg bolus 10 minutes after the first; infusion 1 mcg/kg/min if creatinine clearance is below 50 mL/min | Intravenous | Two boluses, then continuous infusion | Until hospital discharge or up to 18–24 hours, whichever comes first; at least 12 hours recommended | Indicated to decrease the rate of a combined endpoint of death, new myocardial infarction or need for urgent intervention | Eptifibatide injection (Slate Run Pharmaceuticals) — FDA prescribing information, DailyMed |
Where sources disagree
- Eptifibatide is a platelet aggregation inhibitor given in hospital, together with aspirin and heparin as the label sets out. The label warns that it can cause serious bleeding and acute, profound thrombocytopenia; bleeding and low blood pressure are its most common adverse reactions.
- The label contraindicates it in people with recent bleeding or a bleeding disorder, severe uncontrolled hypertension, major surgery within 6 weeks, stroke within 30 days or any hemorrhagic stroke, another intravenous GP IIb/IIIa inhibitor, or dependence on renal dialysis.
- The original brand, Integrilin, is no longer listed on DailyMed; the label cited here is an FDA-approved generic eptifibatide injection label. Safety and effectiveness in children have not been studied, according to the label.